Compare DSL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | MNKD |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2013 | 2004 |
| Metric | DSL | MNKD |
|---|---|---|
| Price | $10.54 | $4.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 546.7K | ★ 3.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 11.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $10.49 | $2.23 |
| 52 Week High | $12.67 | $6.51 |
| Indicator | DSL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 50.66 |
| Support Level | $10.53 | $3.74 |
| Resistance Level | $11.02 | $4.23 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 12.27 | 38.76 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.